US Pre-Market SEC Filings Roundup — June 09, 2026

09-06-2026

Inflection Point Acquisition Corp. III entered into Amendment No. 2 to its Business Combination Agreement with Air Water Ventures Holdings Limited, reducing the aggregate base consideration from $300,000,000 to $200,000,000 and lowering the maximum earnout shares from 30,000,000 to 20,000,000. The amendment also modifies earnout triggers, including revenue and EBITDA run-rate targets through June 2028. No other changes were made to the agreement.

• · The BCA Amendment was entered into on June 5, 2026.
• · Triggering Event I requires annual revenue run rate ≥ $80M by December 31, 2027.
• · Triggering Event II requires annual EBITDA run rate ≥ $30M by December 31, 2027.
• · Triggering Event III requires both annual revenue run rate ≥ $160M and annual EBITDA run rate ≥ $70M by June 30, 2028.
• · Triggering Event IV requires PubCo's share price ≥ $20.00 for 30 of 45 consecutive trading days between six months post-closing and June 30, 2028.
• · The earnout shares are now split into four equal tranches of 5,000,000 ordinary shares each.
• · An updated investor presentation was furnished as Exhibit 99.1.

09-06-2026

Comstock Inc. (LODE) announced a change in its independent registered public accounting firm following the acquisition of Assure CPA, LLC by Sadler, Gibb & Associates, LLC. Assure resigned effective June 3, 2026, and the Board appointed Sadler Gibb as the new auditor on June 5, 2026. There were no disagreements or reportable events with the former auditor, and the audit reports for fiscal years 2024 and 2025 were unqualified.

• · The change in auditor was due to Sadler Gibb acquiring substantially all assets of Assure.
• · The engagement team, including the lead audit partner, has joined Sadler Gibb and will continue to service the Company.
• · Assure has ceased operations as a public accounting firm.
• · No consultations with Sadler Gibb occurred prior to appointment regarding accounting principles or disagreements.

09-06-2026

Pharmaceutical Resource Technology, Inc. filed Amendment No. 4 to its S-1 registration statement for an IPO of up to 100,000,000 shares of common stock at $0.50 per share, with a concurrent resale offering of up to 170,175,496 shares by selling stockholders. The company operates in honey straw manufacturing, pharmaceutical/dietary supplements, and building/construction services in Singapore, with 66% of revenue from construction. However, the offering is self-underwritten on a best-efforts basis with no minimum purchase requirement, meaning the company may raise substantially less than the maximum $49.9 million, and investors face significant dilution and a high risk of total loss.

• · The company is a Wyoming corporation with principal executive offices in Singapore and does not legally own any subsidiaries.
• · Operations are heavily dependent on a related-party relationship with Superbee Network Singapore Pte. Ltd., which provides personnel and operational support; the two executive officers/directors also control Superbee.
• · The offering will terminate upon sale of all shares or 365 days after the effective date (extendable by 90 days by the Board).
• · There is no public market for the stock; the company intends to apply for OTCQB quotation but has no arrangement with any market maker.
• · The offering price of $0.50 per share was arbitrarily determined by management and bears no relationship to assets, earnings, or book value.
• · The company has only two permanent employees (the executive officers/directors).
• · The resale offering by selling stockholders is separate; the company will not receive any proceeds from those sales.
• · Transactions may be subject to penny stock rules, imposing additional broker-dealer obligations.

09-06-2026

Novanta Inc. announced a definitive agreement to acquire Riverpoint Medical for $1.2 billion upfront plus a $250 million milestone payment in Q1 2027, expected to close in Q3 2026. The acquisition is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows, and is projected to double recurring medical consumables revenue to approximately $300 million. However, the upfront purchase price of $1.2 billion represents approximately 19x Riverpoint's estimated 2026 Adjusted EBITDA excluding synergies, indicating a high valuation multiple, and the transaction will increase Novanta's net leverage ratio to approximately 2.7x post-closing.

• · Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
• · Novanta expects net leverage ratio of approximately 2.7x after closing, reducing to below 2.3x by year-end 2027.
• · Transaction financed through cash on hand, existing credit facility, and a $300 million equity raise.
• · Novanta confirms its previously issued Q2 and Full Year 2026 financial guidance for the standalone company and will update guidance post-close.
• · Conference call scheduled for June 9, 2026 at 8:30 a.m. ET.
• · Riverpoint has manufacturing operations in Portland, Oregon and San Jose, Costa Rica.

09-06-2026

CervoMed Inc. held its 2026 Annual Meeting on June 8, 2026, with 67.2% of outstanding shares represented. All eight director nominees were elected, and stockholders ratified RSM US LLP as auditor, approved advisory say-on-pay, and approved Amendment No. 1 to the 2025 Equity Incentive Plan. Notably, broker non-votes were high (3,033,573) on all director and compensation-related proposals, indicating significant abstention by brokers.

• · Record date for voting was April 17, 2026.
• · All eight director nominees were elected with votes ranging from 3,126,987 to 3,155,846 'For' and minimal 'Withheld' votes (29,174 to 58,033).
• · Ratification of RSM US LLP as auditor passed with 6,092,751 For, 21,433 Against, 104,409 Abstain.
• · Advisory say-on-pay passed with 3,073,013 For, 104,221 Against, 7,786 Abstain, plus 3,033,573 broker non-votes.
• · Approval of Amendment No. 1 to the 2025 Equity Incentive Plan passed with 3,044,744 For, 132,860 Against, 7,416 Abstain, plus 3,033,573 broker non-votes.
• · Broker non-votes were 3,033,573 on all proposals except the auditor ratification (which had no broker non-votes).

09-06-2026

AITX filed its audited FY2026 10-K, confirming revenue grew 26% YoY to $7.7M and gross margin expanded to 71% from 61%, while operating expenses remained flat. However, the company reported a loss from operations of $11.9M, an accumulated deficit of ~$165M, and only $144K cash on hand, with auditors issuing a going concern qualification. The company also detailed its three-pillar operating strategy (Stationary, Mobile, Agentic AI) and noted that its residential product line (RAD-R) generated immaterial revenue, substantially below expectations.

• · Auditors issued a going concern qualification due to recurring net losses, negative working capital, ~$165M accumulated deficit, and dependence on external financing.
• · Total liabilities of ~$58M exceed total assets of ~$9M, resulting in a stockholders' deficit of ~$49M.
• · Cash on hand was only ~$144K, insufficient to fund operations for any extended period without additional financing.
• · Approximately 96% of outstanding loans payable are owed to entities controlled by a single individual, creating concentration risk.
• · The residential product line (RAD-R) generated immaterial revenue in FY2026, substantially below expectations.
• · ROAMEO commenced commercial billing in May 2026 after ~$20M in cumulative development investment.
• · The company has experienced significant common share dilution, including issuances under an equity financing arrangement of up to $30M.
• · The company has not been profitable in any fiscal year of its operating history.
• · RAD-G (agentic AI platform) has not yet produced revenue commensurate with management's expectations.
• · The company serves customers including one Fortune Top 10 enterprise and several additional Fortune 500 enterprises.

09-06-2026

Blue Biofuels, Inc. (BIOF) disclosed on June 8, 2026, that its independent auditor, Assure CPA, LLC, resigned after merging into Sadler, Gibb & Associates, LLC. The Audit Committee simultaneously approved the engagement of Sadler Gibb as the new independent registered public accounting firm for fiscal year 2026. No disagreements or reportable events occurred with Assure CPA during the past two fiscal years, though its audit reports included a going concern qualification for both 2024 and 2025.

• · Assure CPA's audit reports for fiscal years 2024 and 2025 contained an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
• · No disagreements or reportable events occurred with Assure CPA during fiscal years 2024 and 2025 and the subsequent interim period through June 3, 2026.
• · The Company did not consult with Sadler Gibb on any accounting, auditing, or financial reporting matters prior to engagement.
• · The resignation and engagement were approved by the Audit Committee on June 8, 2026.

09-06-2026

Inflection Point Acquisition Corp. VI (IPFX) filed a Form 425 with the SEC on June 9, 2026, in connection with its proposed business combination with Quantum Space, LLC. The filing includes social media communications from Quantum Space and its executives (Kam Ghaffarian, Jim Bridenstine, Kerry Wisnosky) promoting the merger, but contains no financial data or performance metrics. The filing is primarily a regulatory disclosure with extensive forward-looking statements and risk factors, highlighting that Quantum Space's flagship vehicle, Ranger, is still in development and has not been manufactured, operated, or sold to date.

• · Quantum Space's flagship vehicle, Ranger, is currently in development and has not been manufactured, operated, or sold to date.
• · Ranger is intended to have a refuelable and modular architecture with an operational life of up to 15 years.
• · The business combination requires shareholder approval and is subject to various closing conditions.
• · Inflection Point's final prospectus for its IPO was filed with the SEC on March 30, 2026 (File No. 333-292443).
• · The filing includes social media posts from Quantum Space and its executives on LinkedIn and X (formerly Twitter) dated June 8, 2026.

09-06-2026

On June 4, 2026, Qorvo's Compensation Committee approved FY2027 performance-based restricted stock unit (PBRSU) awards for named executive officers, with 50% tied to non-GAAP operating income, 25% to gross margin, and 25% to revenue objectives. The committee also granted a retention award to Philip J. Chesley comprising 9,618 service-based RSUs and 9,618 PBRSUs linked to organic HPA revenue growth. The awards reflect shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics. The fair market value per share was set at $103.97.

• · The FY2027 PBRSUs use three performance metrics: non-GAAP operating income (50% weight), gross margin (25%), and revenue (25%).
• · The non-GAAP operating income and gross margin objectives are measured over three one-year periods (FY2027, FY2028, FY2029); the revenue objective is measured over a single one-year period (FY2029).
• · Each officer can earn up to 200% of target PBRSUs for each metric if objectives are fully met.
• · The Retention Award for Mr. Chesley includes 9,618 service-based RSUs vesting in two equal annual installments and 9,618 PBRSUs tied to organic HPA revenue growth over FY2027 and FY2028.
• · The Retention Award PBRSUs have a maximum payout of 100% of target (not 200%).
• · The Retention Award RSUs (but not PBRSUs) will fully vest upon a qualifying termination in connection with a change in control.
• · Upon the closing of the merger with Skyworks, the Retention Award PBRSUs will remain in place and eligible to be earned post-closing, not measured at closing.
• · The fair market value per share for both awards was $103.97, based on the June 4, 2026 closing price.
• · The awards were approved in response to shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics.

09-06-2026

FutureCorp Space Acquisition 1, a blank check company focused on the global space economy, announced the pricing of its $200,000,000 initial public offering of 20,000,000 units at $10.00 per unit. The units are expected to begin trading on the NYSE on June 5, 2026, under the ticker 'FTRAU', with the offering closing on June 8, 2026. The company has granted underwriters a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments.

• · The company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
• · The company's primary focus will be on companies in the global space economy and adjacent industries, including space manufacturing and component supply chains, launch platforms, in-orbit services and habitats, in-orbit computing and manufacturing, space-based telecommunications and Earth observation, and defense-related activities.
• · The registration statement relating to the securities became effective on June 4, 2026.
• · The units are expected to be listed on NYSE under the ticker symbol 'FTRAU'.
• · Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols 'FTRA' and 'FTRAW', respectively.
• · An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering.
• · No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

09-06-2026

Cantor Equity Partners VII, Inc. filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 25,000,000 Class A ordinary shares at $10.00 per share, aiming to raise $250,000,000. The blank check company has not yet selected a business combination target and must complete an initial business combination within 24 months of the offering closing or liquidate. The sponsor purchased 7,187,500 founder shares for $25,000 (approximately $0.003 per share), resulting in immediate and substantial dilution for public shareholders, and has agreed to a private placement of 600,000 Class A shares at $10.00 per share ($6,000,000 aggregate).

• · The company is a blank check company (SPAC) incorporated in the Cayman Islands with SIC code 6770.
• · The underwriters have a 45-day option to purchase up to an additional 3,750,000 Class A ordinary shares to cover over-allotments.
• · Unlike some other SPAC IPOs, this offering does not include warrants for investors.
• · The sponsor note of up to $4,312,500 will not bear interest and is convertible into Class A shares at $10.00 per share no earlier than 60 days after the offering date.
• · If the company fails to complete a business combination within 24 months, it will redeem 100% of public shares from the trust account.
• · Public shareholders have redemption rights upon completion of a business combination, but those holding more than 15% of public shares may be restricted from redeeming without prior consent if a shareholder vote is held.
• · The founder shares (Class B) automatically convert into non-redeemable Class A shares upon consummation of the initial business combination.
• · The company has not initiated any discussions with any business combination target.

09-06-2026

Brilliant N.E.V. Corp. filed an 8-K on June 9, 2026, covering Items 5.01 (Change in Control), 5.02 (Departure of Directors or Principal Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing indicates significant corporate governance changes, including a change in control and officer/director departures, but no specific financial figures or period-over-period comparisons were provided in the filing metadata.

• · The company was formerly known as Clancy Corp (filings through 2023-08-09).
• · The company's SIC code is 2840 (Soap, Detergent, Cleaning Preparations, Perfumes, Cosmetics).
• · Fiscal year ends July 31.
• · The filing includes items related to changes in control, officer/director changes, and amendments to governing documents.

09-06-2026

Cipher Digital Inc. (CIFR) announced that its wholly-owned subsidiary Stingray Compute LLC priced an $810.0M aggregate principal amount of 6.000% senior secured notes due 2031 at 99.750% of par. The offering is expected to close on June 15, 2026, and is being sold to qualified institutional buyers and non-U.S. persons under Rule 144A and Regulation S. There is no prior-period comparative financial data in this filing to calculate period-over-period changes.

• · Notes are being sold exclusively to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
• · The offering is expected to close on June 15, 2026, subject to customary closing conditions.
• · The filing includes cautionary forward-looking statements and incorporates risk factors from the 2025 10-K and Q1 2026 10-Q.

09-06-2026

Uranium Energy Corp (UEC) reported a net loss of $52.3M for Q3 FY2026 (three months ended April 30, 2026), widening from a $30.2M loss in the same quarter last year, driven by higher operating costs and a $19.4M fair value loss on equity securities. For the nine-month period, net loss was $76.6M vs $60.6M a year ago. The company significantly strengthened its balance sheet, raising $508.2M in net proceeds from share issuances, boosting cash to $488.1M from $148.9M at July 31, 2025, while total assets grew to $1.54B. However, sales were nil in Q3 (vs $20.2M in the prior nine months) and operating cash flow burned $90.1M year-to-date.

• · No sales were recorded in Q3 FY2026 (vs nil in Q3 FY2025), while nine-month sales dropped 69.8% to $20.2M from $66.8M.
• · Mineral property expenditures surged 88.4% YoY in Q3 to $29.5M, driven by a 143% increase in development costs ($15.8M vs $6.5M) and a 148% increase in exploration costs ($7.6M vs $3.1M).
• · Fair value loss on equity securities was $19.4M in Q3 FY2026, compared to a $4.3M loss in Q3 FY2025.
• · Interest income rose to $4.2M in Q3 FY2026 from $0.6M in Q3 FY2025, reflecting higher cash balances.
• · Cash used in operating activities more than doubled to $90.1M for the nine months (vs $41.0M).
• · Net cash provided by financing activities was $505.1M, primarily from share issuances ($508.2M).
• · Inventories increased 9.1% to $86.5M, driven by a 635% increase in uranium concentrates from extraction ($8.4M vs $1.1M).
• · Equity-accounted investments rose to $63.8M from $55.8M, and investment in equity securities increased to $65.9M from $28.5M.
• · Total liabilities decreased 5.8% to $116.6M from $123.8M.
• · Weighted average diluted shares outstanding increased 14.1% to 490.7M in Q3 FY2026 from 429.9M in Q3 FY2025.

09-06-2026

Ribbon Acquisition Corp. deposited $125,000 into its trust account to extend the deadline for completing its initial business combination by one month, from May 15, 2026 to June 15, 2026. This is the company's second extension payment, indicating continued but time-pressured progress toward a merger target.

• · The extension moves the deadline from May 15, 2026 to June 15, 2026.
• · The filing was signed on June 8, 2026, and filed on June 9, 2026.
• · Ribbon Acquisition Corp. is a blank check company (SPAC) incorporated in the Cayman Islands, headquartered in Tokyo, Japan.
• · The company's securities (Class A ordinary shares, units, and rights) are listed on Nasdaq under symbols RIBB, RIBBU, and RIBBR respectively.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

09-06-2026

Starton Holdings, Inc. filed Amendment No. 4 to its S-1 registration statement for an initial public offering of 5,000,000 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company is a clinical-stage biotechnology firm focused on improving cancer therapies via proprietary delivery technology. The offering includes a 45-day underwriter option for an additional 750,000 shares, and the company has applied to list on Nasdaq under the symbol 'STA'.

• · The company is a clinical-stage biotechnology company focused on improving standard-of-care therapies for cancer through proprietary delivery technology systems.
• · The company has applied to list its common stock on the Nasdaq Capital Market under the symbol 'STA'.
• · The estimated initial public offering price per share is between $5.00 and $7.00.
• · The underwriters have a 45-day option to purchase up to an additional 750,000 shares to cover over-allotments.
• · The company is an 'emerging growth company' and a 'smaller reporting company' under federal securities laws.
• · The company's principal executive offices are located at 215 College Road, Suite 300, Paramus, NJ 07652.

09-06-2026

For the three months ended March 31, 2026, AIBOTICS, INC. reported net loss of $418,105, an improvement from the $591,397 loss in the same period of 2025, driven primarily by reduced general and administrative expenses ($359,463 vs $531,647). However, revenue dropped to $0 from $2,183 in the prior year, and the company's accumulated deficit widened to $13.44M. Cash used in operating activities increased to $36,258 from $28,360 in the prior year period, while cash and total assets declined modestly.

• · Net cash used in operating activities increased to $36,258 in Q1 2026 from $28,360 in Q1 2025.
• · Interest expense decreased slightly to $58,642 in Q1 2026 from $61,933 in Q1 2025.
• · Cash provided by financing activities was $69,176 in Q1 2026 (proceeds from convertible note payable $98,000, partially offset by repayments of $28,824), compared to $0 in Q1 2025.
• · Total liabilities increased to $5,051,334 as of March 31, 2026, from $4,834,905 as of December 31, 2025.
• · Amortization expense for intangible assets was $169,956 in Q1 2026, up from $164,234 in Q1 2025.
• · Common shares outstanding more than doubled from 45.2M (Mar 31, 2025) to 539.4M (Mar 31, 2026).

09-06-2026

News Corp filed an 8-K on June 9, 2026, disclosing that it has provided daily transaction disclosures to the Australian Securities Exchange (ASX) under its existing $1 billion stock repurchase program. The filing includes forward-looking statements regarding the company's intent to repurchase shares from time to time, subject to market conditions and other factors.

• · The repurchase program authorizes up to $1 billion in aggregate of Class A and Class B common stock.
• · Disclosures were provided to the ASX on the dates noted in Exhibits 99.1 through 99.4.
• · The company disclaims any obligation to update forward-looking statements except as required by law.

09-06-2026

Duos Technologies Group, Inc. announced that effective June 8, 2026, Leah Brown stepped down as Chief Financial Officer to resume her previous role as Senior Vice President of Accounting, and Adrian Goldfarb was appointed Interim Chief Financial Officer. Mr. Goldfarb, who previously served as CFO from April 2024 to November 2025 and from 2015 to 2022, will lead a search committee to hire a permanent CFO, with a replacement expected within 60 to 90 days. The filing does not disclose any financial results or performance metrics, so no positive or negative financial trends are reported.

• · Adrian Goldfarb has been serving as Strategic Advisor to the CEO since November 2025 and as President of Duos Technologies, Inc. since March 2026, overseeing the rail industry subsidiary's operations and planned divestment.
• · Mr. Goldfarb previously served as CFO from April 2024 to November 2025 and from 2015 to 2022, and as a Director from April 2010 to November 2020.
• · He managed the Company's listing on the Nasdaq Capital Market in 2020.
• · Mr. Goldfarb currently serves as non-Executive Chairman of GelStat Corporation.
• · Prior to Duos, he served as CFO for Ecosphere Technologies, overseeing growth from $0 to $24 million and profitability.

09-06-2026

Lionheart Holdings appointed Freddy J. Martinez (age 70) as a Class III director effective June 6, 2026, filling a new board vacancy. The appointment reflects the Company's strategic shift to focus on oil and gas opportunities in Venezuela. Mr. Martinez brings over 40 years of investment management and energy sector experience, with no cash compensation paid for his services.

• · Mr. Martinez is independent under NASDAQ rules and serves as President/CEO of Forem Investments LLC, a registered investment adviser founded in December 2013.
• · He holds an MBA in finance from Wharton, an M.S. in Engineering from the Moore School, and a B.S. in Mechanical Engineering from Universidad Simón Bolívar.
• · The Company's definitive proxy statement for an extension of time through March 20, 2027 was mailed to shareholders of record as of May 15, 2026; a special meeting is scheduled for June 15, 2026.
• · Mr. Martinez has not received any cash compensation; he entered into a standard director indemnification agreement and the Letter Agreement dated June 17, 2024.

09-06-2026

IQM Finland Oy and Real Asset Acquisition Corp. (RAAQ) announced that the SEC declared effective the Registration Statement on Form F-4 for their proposed business combination. The Extraordinary General Meeting of RAAQ shareholders to vote on the transaction is scheduled for June 25, 2026. The filing does not disclose any financial performance metrics, so no positive or negative trends can be reported.

• · The Registration Statement on Form F-4 was declared effective by the SEC on June 5, 2026.
• · RAAQ mailed the definitive proxy statement/prospectus to shareholders as of June 3, 2026, the record date for the Extraordinary General Meeting.
• · The Business Combination Agreement was entered into on February 22, 2026.
• · RAAQ's securities are listed on Nasdaq under symbols RAAQU, RAAQ, and RAAQW.
• · The filing includes forward-looking statements and risk factors related to the transaction and IQM's business.

09-06-2026

Ooma, Inc. held its 2026 Annual Meeting on June 4, 2026, with 85.2% of outstanding shares represented. Stockholders elected two Class II directors (Susan G. Butenhoff and Russ Mann), ratified KPMG LLP as independent auditor for FY ending January 31, 2027, and approved executive compensation on a non-binding advisory basis. However, Susan G. Butenhoff received a significant number of withheld votes (6,022,830 against 12,259,460 for), indicating notable shareholder dissent.

• · The meeting was held on June 4, 2026, and the report was filed on June 8, 2026.
• · Proposal 1 (Director Election): Susan G. Butenhoff received 12,259,460 for and 6,022,830 withheld (approx. 33% withheld of votes cast), while Russ Mann received 17,355,865 for and 926,425 withheld (approx. 5% withheld).
• · Proposal 2 (Auditor Ratification): KPMG LLP was ratified with 23,265,635 for, 17,738 against, and 165,209 abstentions.
• · Proposal 3 (Say-on-Pay): Executive compensation was approved with 17,705,978 for, 528,798 against, and 47,514 abstentions, with 5,166,292 broker non-votes.
• · No other proposals were voted on at the meeting.

09-06-2026

Real Asset Acquisition Corp. (RAAQ) and IQM Finland Oy announced that the SEC declared effective IQM's Registration Statement on Form F-4 for their proposed business combination, which will make IQM a publicly traded company. RAAQ has mailed the definitive proxy statement/prospectus to shareholders as of June 3, 2026, with an Extraordinary General Meeting to be held to vote on the transaction.

• · The Business Combination Agreement was entered into on February 22, 2026.
• · The Registration Statement was declared effective by the SEC on June 5, 2026.
• · Shareholders of record as of June 3, 2026 are entitled to vote at the Extraordinary General Meeting.
• · The combined company's securities (RAAQU, RAAQ, RAAQW) trade on The Nasdaq Stock Market LLC.
• · The exercise price for redeemable warrants is $11.50 per Class A ordinary share.

09-06-2026

First Nebraska Trust Co filed its quarterly 13F-HR for the period ending September 30, 2025, reporting total holdings of approximately $1.11 billion across 205 equity positions. The portfolio is heavily weighted toward large-cap U.S. equities, with top holdings including Apple Inc. ($70.9M), Berkshire Hathaway Inc. Class B ($47.3M), and Microsoft Corp. ($44.2M). The filing reflects a diversified investment strategy with significant exposure to technology, healthcare, and consumer staples sectors.

09-06-2026

AN2 Therapeutics, Inc. held its 2026 annual meeting on June 3, 2026, with a quorum of 22,741,535 shares (63.18% of outstanding shares). Stockholders elected three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. All proposals passed, though director Kabeer Aziz received a notable 22.6% withheld vote (3,958,874 votes withheld), indicating some shareholder dissent.

• · The annual meeting was held on June 3, 2026, with a record date of April 15, 2026.
• · Director Kabeer Aziz received 13,547,536 votes for and 3,958,874 withheld (22.6% withheld of votes cast), significantly higher than the other two directors (Marks: 8.9% withheld; Readnour: 9.1% withheld).
• · Ratification of PwC as auditor passed overwhelmingly with 22,724,674 votes for, only 13 against, and 16,848 abstentions.
• · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

09-06-2026

XOMA Royalty Corp filed an S-4/A registration statement detailing its proposed merger with a subsidiary of Ligand Pharmaceuticals Incorporated. The merger, expected to close in Q3 2026, will result in XOMA Royalty stockholders receiving cash and CVRs, with dissenter's rights available under Nevada law. XOMA Royalty reported total cash receipts of $50.5 million in 2025, comprising $33.6 million in commercial payments and $16.9 million in milestone payments and other fees, though the filing did not provide comparable prior-period data for context. Risks include a $40.0 million termination fee under certain conditions if the merger is not completed.

• · Special Meeting to vote on proposals scheduled for July 13, 2026, at 9:00 a.m. PT via virtual meeting.
• · Record date for the Special Meeting is June 5, 2026.
• · Approval of Merger Agreement Proposal requires affirmative vote of holders of a majority of outstanding voting power; abstentions and broker non-votes count against.
• · Holding Company Reorganization Proposal approval is conditioned on Merger Agreement Proposal approval.
• · Merger is taxable for U.S. federal income tax purposes; tax treatment of CVRs is uncertain.
• · Closing conditions include stockholder approval, no adverse government action, expiration of HSR Act waiting period, and completion of Holding Company Reorganization.
• · If merger is not completed, XOMA Royalty remains an independent public company and its common stock continues trading on Nasdaq.

09-06-2026

Cantor Equity Partners I, Inc. (CEPO) filed a DEFA14A regarding its pending business combination with BSTR Holdings, Inc. and BSTR Newco, LLC. BSTR Newco increased its loan facility from $2.5M to $3.6M via an amendment on June 2, 2026, with the additional $1.1M accruing interest at SOFR plus 3.90%. The registration statement for the business combination was declared effective by the SEC on June 5, 2026, and the definitive proxy statement/prospectus has been mailed to CEPO shareholders as of the June 5, 2026 record date.

• · The registration statement on Form S-4 (No. 333-295863) was declared effective by the SEC on June 5, 2026.
• · The record date for voting on the business combination is June 5, 2026.
• · Interest on the loan is payable annually starting on the first anniversary of the Loan Agreement (March 15, 2027).
• · The loan matures upon the earliest of: (i) consummation of the business combination, (ii) dissolution of BSTR, or (iii) two years from signing (March 15, 2028).
• · BSTR may prepay the principal at any time without premium or penalty.

09-06-2026

Axos Financial, Inc. announced that its subsidiary Axos Bank received OCC approval for a previously disclosed deposit acquisition, which is expected to close later in 2026.

• · The approval was granted on June 8, 2026.
• · The transaction was initially disclosed on April 23, 2026.

09-06-2026

Enveric Biosciences, Inc. filed an 8-K on June 8, 2026, announcing the release of its Q2 2026 Investor Presentation, which management intends to use in discussions with investors, analysts, and other stakeholders. The presentation is furnished under Regulation FD and is available on the company's website. No specific financial figures or performance data were disclosed in the filing itself.

• · The Investor Presentation is furnished as Exhibit 99.1 and incorporated by reference into the 8-K.
• · The presentation is available on the company's website at https://www.enveric.com/investors/events/.
• · The information in this 8-K is not deemed 'filed' for purposes of Section 18 of the Exchange Act and is not incorporated by reference into any SEC filings unless expressly set forth.

09-06-2026

BTCS Inc. held its 2026 Annual Meeting on June 8, 2026, where all six proposals were approved by shareholders, including the election of directors Charles Allen, Charles Lee, and Ashley DeSimone, and the ratification of Forvis Mazars, LLP as independent auditor. Separately, on June 5, 2026, the company repaid $8.7 million of principal indebtedness under its Aave borrowing arrangement, reducing outstanding debt to approximately $35.7 million (including accrued interest). While shareholder support was strong for most proposals, Proposal 5 (adding an evergreen provision to the equity plan) passed with a relatively narrow margin of 12,196,037 for vs. 6,421,729 against, indicating notable opposition.

• · Proposal 5 (evergreen provision) passed with 12,196,037 for vs. 6,421,729 against, a relatively narrow margin compared to other proposals.
• · Proposal 3 (increase authorized shares to 24.5M) also saw significant opposition: 12,471,715 for vs. 6,162,939 against.
• · Broker non-votes totaled 13,270,443 on all director elections and equity plan proposals, indicating substantial institutional or street-name holdings.
• · The company repaid $8.7M of Aave debt on June 5, 2026, leaving $35.7M outstanding (including accrued interest).

09-06-2026

Synchrony Financial filed an 8-K on June 9, 2026, furnishing monthly charge-off and delinquency statistics for the thirteen months ended May 31, 2026, under Regulation FD. The company intends to continue providing these statistics monthly, with quarter-end data released alongside quarterly financial results. No specific financial figures or performance trends were disclosed in the filing text itself.

• · The filing is a Regulation FD disclosure, not a filed report, and is not incorporated by reference into other SEC filings.
• · Exhibit 99.1 contains the actual monthly charge-off and delinquency statistics for the thirteen months ended May 31, 2026.
• · The company will continue to furnish these statistics monthly, with quarter-end data released alongside quarterly financial results.

09-06-2026

Onconetix, Inc. filed an S-1 registration statement for a proposed securities offering. The company is a commercial-stage biotechnology firm focused on oncology, owning Proclarix, an in vitro diagnostic test for prostate cancer approved in the EU and being developed in the U.S. via a LabCorp agreement. However, the company has incurred net losses since inception, abandoned commercialization of its only other product (ENTADFI), and faces substantial doubt about its ability to continue as a going concern, with cash of only $3.7 million as of March 31, 2026, and an accumulated deficit of $135.4 million.

• · Proclarix is CE-marked and for sale in Europe; in the UK, ~100 tests were carried out in a screening initiative as of March 31, 2026.
• · Two peer-reviewed publications on Proclarix were published in Q1 2026: one in BMC Cancer (Schiess et al., 371 men) and one in Cancers (Athanasiou et al., 132 men).
• · Proteomedix initiated a multi-center PRIME study with LabCorp to evaluate Proclarix in the U.S., targeting up to 500 men; first participants enrolled.
• · The company abandoned commercialization of ENTADFI as of December 31, 2025, and terminated three employees involved with the program.
• · Onconetix has no internal manufacturing capabilities and relies on single-source third-party suppliers for Proclarix.
• · The company believes its current cash balance is not sufficient to fund operations for one year from the date of issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

09-06-2026

Aeon Acquisition I Corp. adopted a Second Amended and Restated Memorandum and Articles of Association on June 2, 2026, filed via an 8-K on June 9, 2026. The updated governing documents formalize the company's structure as a Cayman Islands exempted company limited by shares, with an authorized share capital of $50,000 divided into 450,000,000 Class A ordinary shares, 45,000,000 Class B ordinary shares, and 5,000,000 preference shares, all at $0.0001 par value. The company is designated as a special purpose acquisition company (SPAC) with a 12-month (extendable to 18-month) completion window to consummate a business combination valued at least 80% of trust assets, and it retains the power to register by continuation outside the Cayman Islands.

• · The company is incorporated in the Cayman Islands with registered office at Cassia Court, Suite 716, 10 Market Street, Camana Bay, Grand Cayman KY1-9006.
• · The financial year end is December 31.
• · The company has the power to register by continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands.
• · The business combination must involve a target business with an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding deferred underwriting commissions and taxes on interest income).
• · The company may not effectuate a business combination solely with another blank check company or similar company with nominal operations.
• · The Over-allotment Option allows underwriters to purchase up to an additional 15% of the units issued in the IPO at $10 per unit, less underwriting discounts and commissions.
• · The company is prohibited from issuing shares to bearer.

09-06-2026

NusaTrip Inc. announced multiple executive changes on June 2, 2026, including the appointment of Loïc Gautier as CFO (annual base salary $150,000), Binglin Yu as CTO (RMB 55,000/month), and Hongwei Zhang as Chief Revenue Officer (RMB 55,000/month, effective June 20). The company also removed COO Ade Irawan effective June 2, and entered into an employment agreement with CEO Patrick Soetanto Tjin (base salary $150,000/year plus minimum 25% performance bonus). Notably, the previously announced CFO appointment of Wallace Tzi Chun Foo did not proceed due to personal reasons.

• · CFO appointment of Wallace Tzi Chun Foo did not become effective due to personal and family reasons; no disagreement with the company.
• · New CFO Loïc Gautier has over 10 years of experience in technology, e-commerce, and corporate finance in Southeast Asia; founded Leflair, acquired by SOPA in 2021; helped SOPA with its Nasdaq IPO in 2022.
• · New CTO Binglin Yu holds a Bachelor of Science in Computer Science and Technology from Peking University.
• · New CRO Hongwei Zhang holds an MBA from Pennsylvania State University and is fluent in English and Mandarin.
• · Former COO Ade Irawan was removed from all officer, management, banking, administrative, platform access, and other authorized capacities with the company and its subsidiaries.
• · CEO Patrick Soetanto Tjin's employment agreement includes a minimum 25% performance bonus based on base salary.
• · CRO Hongwei Zhang previously worked at INTECH TRAVEL GROUP, a principal airline content supplier to NusaTrip, from November 2023 to September 2025.

09-06-2026

Brand Engagement Network Inc. (BEN) entered into a definitive agreement on June 8, 2026, to form INTERVENT Health AI, Inc., a 50/50 healthcare AI joint venture with INTERVENT International, LLC. The JV will develop AI-powered health coaching solutions combining BEN's conversational AI with INTERVENT's clinically validated methodologies and datasets. BEN, through its subsidiary SKYE AI USA, will receive 35% of certain JV revenues from North American commercialization under a five-year exclusive arrangement, while the JV will receive 50% of gross revenues from proposed non-exclusive international reseller deals in Latin America and Africa. No financial performance metrics or revenue projections were disclosed, and the agreement is subject to performance milestones.

• · The JV's Board of Directors will consist of one BEN-appointed director, one INTERVENT-appointed director, and one mutually agreed independent director.
• · The Shareholder Agreement includes customary governance, pre-emptive rights, and ownership protection provisions, including restrictions on issuances that would reduce either founding shareholder below specified ownership thresholds without approval.
• · BEN is an emerging growth company as defined under SEC rules.
• · The agreement is subject to performance milestones for the five-year exclusive North American arrangement.

09-06-2026

Parabilis Medicines, Inc. filed an S-1/A registration statement for an initial public offering of 33,333,334 shares of common stock at an assumed price of $18.00 per share, with an overallotment option for up to 5,000,000 additional shares. The company expects net proceeds of approximately $553.1 million from the offering (or $636.8 million if the overallotment is exercised in full), plus an additional $75.0 million from a concurrent private placement with Regeneron. However, the company is not yet profitable, with net losses increasing from $117.9 million in 2024 to $145.9 million in 2025, and a net loss of $45.3 million for the three months ended March 31, 2026, compared to $38.3 million in the same period of 2025.

• · The company has granted the underwriters a 30-day overallotment option to purchase up to 5,000,000 additional shares.
• · Regeneron has agreed to purchase approximately $75.0 million in shares at 90% of the IPO price in a concurrent private placement, contingent on the IPO closing.
• · Pro forma as adjusted cash and cash equivalents after the offering and private placement would be approximately $957.1 million.
• · The company had an accumulated deficit of $586.8 million as of March 31, 2026.
• · Pro forma net loss per share (basic and diluted) for the year ended December 31, 2025 was $(1.81), and for the three months ended March 31, 2026 was $(0.56).
• · The company's convertible preferred stock balance of $814.5 million will convert to common and non-voting common stock upon the closing of the offering.
• · Interest income decreased 47.2% from $6.4 million in 2024 to $3.4 million in 2025, but increased 93.2% from $1.3 million in Q1 2025 to $2.4 million in Q1 2026.
• · Sublease income from a related party was $4.2 million in both 2024 and 2025, but was $0 in Q1 2026 compared to $1.1 million in Q1 2025.
• · The company effected a 1-for-1.5389 reverse stock split on June 3, 2026.
• · The proposed Nasdaq Global Market trading symbol is 'PBLS'.

09-06-2026

U.S. GoldMining Inc. issued a press release on June 9, 2026, providing updates on its 2026 exploration program and district infrastructure catalysts at its 100% owned Whistler Project in Alaska. The filing is a Regulation FD disclosure and does not contain any financial results or quantitative data.

• · The press release is attached as Exhibit 99.1 and is incorporated by reference.
• · The information is furnished, not filed, under Item 7.01 and is not subject to Section 18 liability.

09-06-2026

Designer Brands Inc. reported Q1 2026 net sales of $696.4 million, up 1.4% YoY, with gross margin expanding 240 bps to 45.3%. However, total comparable sales declined 1.1%, and the Retail segment net sales were essentially flat at $626.7 million (down 0.1%). Adjusted diluted EPS of $0.07 exceeded expectations, and the company reaffirmed full-year 2026 EPS guidance of $0.28-$0.38, trending toward the high end.

• · Reported net income was $1.2 million, or diluted EPS of $0.02.
• · Adjusted net income was $3.8 million, or adjusted diluted EPS of $0.07.
• · Cash and cash equivalents totaled $50.1 million, with $138.5 million available under credit facility.
• · Debt decreased to $475.3 million from $522.9 million YoY.
• · Inventories decreased to $586.6 million from $623.6 million YoY.
• · Store count decreased by 6 stores YoY to 663, with total square footage down 1.1%.
• · Full-year 2026 guidance: net sales change -1% to +1%, diluted EPS $0.28-$0.38.
• · Prior period financials were restated due to incorrect duty rates on Topo branded products; immaterial adjustments made for Q1 2025 through Q3 2025.
• · Conference call scheduled for June 9, 2026 at 8:30 am ET; replay available until June 23, 2026.

09-06-2026

Lands' End reported Q1 FY2026 net revenue of $238.9M, down 8.5% YoY from $261.2M, primarily due to a temporary disruption from a warehouse management system rollout. However, Europe eCommerce revenue grew 14.5% YoY to $20.5M, and net income surged to $330.7M ($10.56 per diluted share) from a net loss of $8.3M in Q1 2025, driven by the WHP Global joint venture transaction. Adjusted net loss improved to $3.5M from $5.4M, but adjusted EBITDA turned negative at -$6.2M versus $9.5M a year ago, and gross margin contracted 410 basis points to 46.7%.

• · Net income of $330.7M was primarily driven by the WHP Global transaction, not core operations.
• · Adjusted diluted loss per share improved to $0.11 from $0.18 in Q1 2025.
• · Selling and administrative expenses rose 2.4% to $126.5M, deleveraging to 53.0% of net revenue from 47.3%.
• · Net cash used in operating activities increased sharply to $74.2M from $22.5M a year ago.
• · The company fully repaid its term loan using $300M in proceeds from the WHP Global transaction.
• · ABL facility borrowings decreased to $30.0M from $40.0M, with availability increasing to $104.2M from $86.8M.
• · Q2 FY2026 guidance: net revenue $290M-$310M, adjusted net income $2M-$5M, adjusted EBITDA $11M-$14M.
• · Full-year FY2026 guidance: net revenue $1.30B-$1.40B, adjusted net income $10M-$20M, adjusted EBITDA $68M-$78M.
• · The company repurchased only $0.3M of stock under the $100M buyback program in Q1.
• · Europe eCommerce gross margin expanded approximately 70 basis points despite overall margin compression.

09-06-2026

Nathan's Famous, Inc. reported fiscal 2026 revenue growth of 9.4% to $162.1M, driven by a 15.2% increase in Branded Product Program sales to $105.8M. However, net income declined 16.7% to $20.0M ($4.85 per diluted share) from $24.0M ($5.87 per diluted share) in fiscal 2025, primarily due to a 19% increase in beef costs that compressed margins. The Board declared a quarterly cash dividend of $0.50 per share, and the pending acquisition by Smithfield Foods for $102.00 per share (total enterprise value ~$450M) is now expected to close in the second half of 2026.

• · License royalties were flat at $37.4M in fiscal 2026 vs fiscal 2025, reflecting stability in the licensing business and steady income from the Smithfield Foods agreement.
• · Branded Product Program income from operations fell 40.0% to $4.3M despite a 15.2% sales increase, due to a 19% rise in beef costs.
• · Company-owned restaurant sales declined 1.6% to $12.5M, impacted by lower foot traffic from unfavorable weather at Coney Island locations during the key summer season.
• · Franchise operations revenues increased 4.1% to $4.3M, with franchise restaurant sales up 4.8% to $70.1M; 23 franchised locations opened and 32 closed during fiscal 2026.
• · Advertising revenue was essentially flat at $2.1M.
• · The Board declared a quarterly cash dividend of $0.50 per share, payable June 30, 2026 to shareholders of record June 22, 2026.
• · The pending acquisition by Smithfield Foods for $102.00 per share (total enterprise value ~$450M) is now expected to close in the second half of 2026, delayed from prior timeline due to CFIUS review delays from the partial government shutdown.
• · Corporate expenses increased significantly to $14.0M in fiscal 2026 from $10.3M in fiscal 2025, driven by transaction costs related to the Merger Agreement.

09-06-2026

Titan Machinery reported a net loss of $12.6 million for Q1 FY2027, improved from a $13.2 million loss in Q1 FY2026, with revenue declining 12.1% to $522.4 million. Gross profit margin improved to 17.1% from 15.3% due to stronger equipment margins and a higher mix of parts and service revenue, but adjusted EBITDA fell to $1.0 million from $2.6 million. The company reaffirmed its full-year FY2027 guidance, expecting continued challenges in agriculture and Europe segments.

• · Loss per diluted share improved to $0.55 from $0.58 in the prior year quarter.
• · Total inventories increased by $11.7 million to $914.8 million from January 31, 2026.
• · Outstanding floorplan payables rose to $589.0 million from $553.8 million as of January 31, 2026.
• · The company reaffirmed full-year FY2027 guidance: Agriculture revenue down 15%-20%, Construction flat to up 5%, Europe down 20%-25%, Australia up 10%-15%, adjusted EBITDA $17M-$29M, adjusted diluted loss per share ($1.25)-($1.75).
• · The German business wind-down is expected to reduce Europe segment revenue by approximately $44.4 million in FY2027 (from $53.9M in FY2026 to ~$9.5M).
• · Operating expenses as a percentage of revenue increased to 18.1% from 16.2% year-over-year.
• · The Australia segment pre-tax loss widened to $1.8 million from $0.6 million, despite revenue growth.
• · Net cash used in operating activities was $23.1 million, compared to net cash provided of $6.2 million in the prior year.

09-06-2026

J.M. Smucker Co. reported strong Q4 FY2026 results with net sales up 6% to $2.27 billion and adjusted EPS rising 20% to $2.77, driven by higher net price realization across key segments. However, full-year FY2026 adjusted EPS declined 10% to $9.15 on a net loss of $1.30 per share due to impairment charges, and the company provided a cautious FY2027 outlook with net sales expected to decline 3-4%, partially offset by adjusted EPS growth of 7-12%.

• · Net loss per share for FY2026 was $1.30, primarily due to noncash goodwill impairment charges for the Sweet Baked Snacks reporting unit and Hostess brand trademark recognized in Q3.
• · U.S. Retail Coffee segment profit margin declined 280 bps to 25.8% despite 12% sales growth, as higher costs and unfavorable volume/mix offset price gains.
• · Sweet Baked Snacks sales declined 5% (or 4% excluding divestiture impact) driven by 12% volume/mix decline, though profit rose 45% on price and lower marketing.
• · Away From Home segment was reclassified as a reportable segment during Q4; it posted 15% sales growth with 21% profit growth.
• · Full-year FY2026 net loss was driven by impairment charges; adjusted EPS fell 10% despite 4% sales growth, reflecting margin compression.
• · FY2027 guidance projects net sales decline of 3-4% but adjusted EPS growth of 7-12%, implying margin expansion through cost actions.
• · Coffee segment's 21 ppt price increase was substantially offset by an 8 ppt volume/mix decline, indicating consumer trade-down or elasticity.
• · Free cash flow for FY2026 doubled to $1.2B from $816.6M, supporting $720M debt repayment and $464.7M in dividends.

09-06-2026

Zeo ScientifiX, Inc. announced on June 9, 2026, the expansion of its Medical Advisory Board with the addition of nine physicians and scientific innovators in regenerative and longevity medicine. This filing contains no financial or operational performance data, and no comparisons to prior periods are available.

• · The event was reported under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
• · The press release is attached as Exhibit 99.1 to the 8-K filing.
• · The company is incorporated in Nevada and headquartered in Davie, Florida.

09-06-2026

GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124 per share in cash), representing a 40% premium to the last closing price. The deal includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer currently under FDA review with target decision dates in September and November 2026, plus a phase I HER2 inhibitor (NVL-330). The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, but will cause low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028.

• · The transaction is expected to close in Q3 2026, subject to tender of a majority of Nuvalent's Class A shares and HSR Act clearance.
• · GSK will assume Nuvalent's existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
• · The acquisition will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating.
• · GSK reaffirmed its 2026 dividend of 70p and progressive dividend policy.
• · GSK's FY 2026 guidance of 7-9% core operating profit and core EPS growth remains unchanged.
• · GSK expects low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028 from the transaction.
• · The acquisition is expected to be accretive to core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.
• · Zidesamtinib has a target FDA decision date of 18 September 2026; neladalkib has a target decision date of 27 November 2026.
• · Both zidesamtinib and neladalkib have received FDA Breakthrough Therapy and Orphan Drug Designations.
• · The deal includes Nuvalent's preclinical portfolio of multiple programmes.

09-06-2026

UNFI reported Q3 FY26 net sales of $7.7B (down 4.2% YoY including ~450bps from optimization actions) and swung to net income of $33M from a net loss of $7M in Q3 FY25. Adjusted EBITDA rose 16.6% to $183M and Adjusted EPS increased 75% to $0.77. However, free cash flow declined sharply to $54M from $119M YoY (-54.6%) and operating cash flow fell 43.4% to $98M. The company narrowed its FY26 outlook ranges while maintaining midpoints for all key metrics.

• · Gross profit rate improved 20 bps YoY to 13.6% from 13.4%, benefiting from network optimization and customer mix.
• · Operating expenses decreased to 12.4% of net sales from 12.7% YoY, driven by insurance proceeds and cost savings.
• · Interest expense net declined to $31M from $36M YoY due to lower average debt.
• · Effective tax rate was 21.4% on pre-tax income vs. a benefit rate of 56.3% on pre-tax loss in Q3 FY25.
• · Net debt decreased $46M from Q2 FY26 and $296M from Q3 FY25.
• · Net leverage ratio improved to 2.5x (lowest since fiscal 2018).
• · Total liquidity was ~$1.25B at Q3 FY26 end ($43M cash + $1.20B unused ABL capacity).
• · ABL facility amended and restated during Q3, extending maturity to April 2031.
• · Narrowed FY26 outlook: Net sales $31.1B-$31.3B; Net income $55M-$70M; EPS $0.90-$1.10; Adjusted EPS $2.40-$2.60; Adjusted EBITDA $685M-$705M; Capex ~$250M; Free cash flow ~$330M (midpoints unchanged).